Blepharoplasty in Belem Brazil
Blepharoplasty in Belem section, includes general infrmation about Blepharoplasty Procedure, Blepharoplasty Belem Local News, Blepharoplasty Belem Surgeon Locator and other Blepharoplasty related material.
Blepharoplasty Procedure
This cosmetic surgical procedure intends to reshape the upper eyelid or lower eyelid by the removal and/or repositioning of excess tissue. The procedure also reinforces the surrounding muscles and tendons.
Medical needs
When an advanced amount of upper eyelid skin is present, the skin may hang over the eyelashes and cause of loss of peripheral vision. The outer and upper parts of the visual field are most commonly affected. Such condition may result in difficulty with activities such as driving or reading.
Cosmetic needs
Patients with a less severe amount of excess skin may still wish to undergo similar procedure for cosmetic reasons. Lower eyelid blepharoplasty is almost always done for cosmetic reasons, to improve puffy lower eyelid "bags" and reduce the wrinkling of skin.
The procedure
Blepharoplasty is performed through external incisions made along the natural skin lines of the eyelids. Such location may be the creases of the upper lids and below the lashes of the lower lids, or from the inside surface of the lower eyelid.
Duration
The operation takes one to three hours to complete, depending on the scope of the procedure. Initial swelling and bruising take one to two weeks to resolve. However, until the final result becomes stable, it needs at least several months to heal.
The outcome
The cosmetic outcome of the procedure depends on the anatomy of the upper/lower eyelids, the patients' skin quality, the patients' age, and the bony tissues and soft tissues which are adjacent to the location the Blepharoplasty took place.
Complications
There are factors known to cause complications after surgery. Failure to recognize such factors before the operation may result in undesired outcome. For example, such factors may be:
• Pre-existing dry eyes. The situation after operation may become worse, by disrupting the natural tear film;
• Laxity (looseness) of the lower lid margin (edge), which caused lower lid malposition;
• Prominence of the eye in relation to the malar (cheek) complex, which causes lower lid malposition.
Average costs
Average physician/surgeon fee for blepharoplasty (aesthetic plastic surgery) in 2005 was around $3,000. These fees are for the physician/surgeon fees only and do not include fees for the surgical facility, anesthesia, medical tests, prescriptions, surgical garments or any other costs related to the surgery. Physicians most qualified to perform blepharoplasty are plastic surgeons, otolaryngologies, ophthalmologists, and those that practice oral and maxillofacial surgery.
Asian blepharoplasty
An upper blepharoplasty in someone who is Asian is termed Asian blepharoplasty or double eyelid surgery. It is the most popular form of cosmetic surgery among those of East and Southeast Asian background. Due to anatomic differences between the Asian and occidental eyelid, about half of this population are born without a supratarsal eyelid crease and are called single-lidded. Surgery can be used to artificially create a crease above the eye.
Transconjunctival blepharoplasty
Transconjunctival blepharoplasty involves removing lower eyelid fat through an incision on the back of the eyelid, eliminating the need for an external incision. Since there is no external incision, excess skin can not be removed during the surgery, but skin resurfacing with a chemical peel or carbon dioxide laser may be performed simultaneously. This allows for a faster recovery process.
Other Blepharoplasty Procedures
All Face Procedures
Blepharoplasty belem (current)
belem BOTOX® Cosmetic
belem Ear Surgery
belem Facelift
belem Browlift
More Belem info...
Belem Understand
Bel?m is on the banks of the Bay of Guajar?, which is formed by a set of islands and river mouths on the estuary of the Amazon river. Its river port helps putting into motion the Northern region of Brazil.
The city was established in 1616, after the construction of "Forte do Pres?pio", today "Forte Castelo", at the banks the Par? river. Bel?m is, in a way, a synthesis of the culture and the history of Par? and the Amazon.
-
Belem Eat
A?a?: soup-like dessert made from the A?a? fruit.
Mani?oba: stew with pork and meat in a gravy made from manioc leaves (looks strange but tastes delicious).
Pato no Tucup?: duck with jamb? (vegetable) cooked in tucup?.
Tacac?: soup with tucup?, dried shrimps and jamb?.
Regional Ice Creams: made with fruits like A?a?, Cupua??, Tapereb?, Bacur?, etc. Best ice cream maker is Sorveteria Cair?. -
Plastic Surgery News...
- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced the acceptance of an abstract describing the results of a study using Xibrom(TM) (bromfenac ophthalmic solution) 0.09% therapy in combination with Lucentis(R) (ranibizumab injection) in patients with age-related macular degeneration (AMD). According to the abstract, patients who received Xibrom required 1.6 +/- 0.
- BioSpace has reported briefly on Phase III data for retigabine, a first-in-class neuronal potassium channel opener which is in development as an adjunct in the treatment of adult epilepsy patients with refractory partial-onset seizures.
The double-blind trial – RESTORE 1 (Retigabine Efficacy and Safety Trials for Partial Onset Epilepsy) – randomised 306 adults who were experiencing refractory partial-onset seizures despite receiving stable doses of up to three anti-epileptics to additional treatment with retigabine (400mg TDS; n=151) or placebo (n=150). Study duration was 32 weeks including 8 weeks baseline phase, 6 weeks titration phase, 12 weeks maintenance phase and 6 weeks transition phase. Only brief details of the study are included in the BioSpace abstract which prevents a full evaluation of the findings; however the following results were reported:
• The median reduction in 28-day total partial seizure frequency was 44.3% in the retigabine group and 17.5% in the placebo group (p<0.0001)
• The median reduction in 28-day total partial seizure frequency during the maintenance phase was 54.5% versus 18.9%, respectively (p<0.0001)
• The responder rate (at least a 50% reduction in 28-day total partial seizure frequency) was 45.0% versus 18.0%, respectively (p<0.0001)
• The responder rate during the maintenance phase was 55.5% versus 22.6%, respectively (p<0.0001)
Results from RESTORE 2, the second pivotal Phase III clinical trial studying lower doses of retigabine, are expected during the second quarter of 2008. The company anticipate filing a Marketing Authorization Application (MAA) to the EMEA before the end of the year.